Follow a programme’s mechanism, development history and experimental evidence.
Life Biosciences
ER-100 brings controlled cellular reprogramming into a Phase 1 study of optic nerve disease. Life Biosciences has announced an interim presentation for 8 October 2026. As of 4 October, those findings have not been presented in the verified sources.
Insilico Medicine
Rentosertib connects AI-assisted target selection and molecular design with published lung-disease trial results. A September 2026 analysis examined ageing clocks in stored samples. The developer also announced first dosing in a larger Phase 3 study; the medicine remains experimental.
NewLimit
NewLimit develops reprogramming payloads for liver, immune and vascular cells. The company reports animal work on its first liver candidate and plans human studies in 2027.
Retro Biosciences
Retro's reprogramming portfolio includes stem-cell and tissue approaches. Its collaboration with OpenAI has reported engineered transcription factors that improve pluripotency-marker expression in human cells. That laboratory result does not establish a clinical reprogramming therapy or additional years of human life.
Shift Bioscience
Shift searches for interventions that alter age-associated cell states. Its public portfolio separates the single-factor SB000 laboratory work from an SB101 antifibrotic siRNA programme with company-reported mouse evidence. Neither was verified as a human clinical rejuvenation study.
Altos Labs
Altos studies how cells regain health and resilience, combining experimental biology with computational modelling. This is an organisation-level research programme. Foundational cell and animal studies support its approach; no named clinical rejuvenation candidate or human outcome was verified in this dossier.
UNITY Biotechnology
UNITY tested a senolytic eye injection against an established treatment for diabetic macular oedema. ASPIRE missed its prespecified primary comparison. A later analysis reported noninferiority at week 36. UNITY subsequently closed its operating business.
Mayo-origin senolytic research and collaborating academic groups
Academic groups are testing whether a drug combination can remove senescent cells and improve particular diseases. Human results include tissue-marker changes, a negative primary bone endpoint and a small positive liver-fibrosis trial. These are distinct experiments with different populations and outcomes.
Rejuvenate Bio
Rejuvenate Bio proposes using the liver to produce a circulating protein intended to affect diseased heart tissue. RJB-0402 is aimed at arrhythmogenic cardiomyopathy. Public sources document preclinical work and trial preparation, but do not verify a human intervention study start.
LyGenesis
LyGenesis transplants donor liver cells into abdominal lymph nodes, where it aims to grow auxiliary liver tissue. Human testing began in 2024. A subsequent safety review supported continuation, while detailed human efficacy results remain unverified in the sources checked.
eGenesis
eGenesis engineers pig kidneys to address immune incompatibility and pathogen risks in transplantation. Expanded access has supplied early human evidence. A formal trial remains a planned next step, with its proposed start distinguished from the evidence already reported.
XPRIZE Foundation and participating research teams
XPRIZE Healthspan organises a competition around improvements in muscle, cognitive and immune function. Twenty teams entered the finals in August 2026. Its contribution is a shared trial and measurement framework; finalist selection is not evidence that a competing intervention has achieved the prize's target.
Academic collaborations at Memorial Sloan Kettering and Cold Spring Harbor Laboratory
Researchers have engineered T cells to recognise uPAR, a surface protein associated with senescence. Mouse studies test whether clearing these cells improves metabolism and intestinal function.
Broad Institute, MIT and academic collaborators
A mouse study uses liver-directed mRNA to supply immune signals. The research tests a temporary change in immune function.
No programmes match these filters. Try a broader search.
